SON

Chr 21AD

SON DNA and RNA binding protein

Also known as: BASS1, C21orf50, DBP-5, NREBP, SON3, TOKIMS

This gene encodes a protein that contains multiple simple repeats. The encoded protein binds RNA and promotes pre-mRNA splicing, particularly of transcripts with poor splice sites. The protein also recognizes a specific DNA sequence found in the human hepatitis B virus (HBV) and represses HBV core promoter activity. There is a pseudogene for this gene on chromosome 1. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2013]

GeneReviewsOMIMResearchGenerating clinical summary…
LOFmechanismADLOEUF 0.121 OMIM phenotype
Clinical SummarySON
🧬
Gene-Disease Validity (ClinGen)
ZTTK syndrome · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
154 unique Pathogenic / Likely Pathogenic· 764 VUS of 1776 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available
📖
GeneReview available — SON
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

LoF intolerant — likely haploinsufficient
LoF Constraint?
0.12LOEUF
pLI 1.000
Z-score 7.74
OE 0.05 (0.020.12)
Highly constrained

Among the most LoF-intolerant genes (~top 3%)

Missense Constraint?
1.54Z-score
OE missense 0.88 (0.840.93)
1187 obs / 1346.1 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.05 (0.020.12)
00.351.4
Missense OE?0.88 (0.840.93)
00.61.4
Synonymous OE?1.21
01.21.6
LoF obs/exp: 4 / 77.5Missense obs/exp: 1187 / 1346.1Syn Z: -3.65
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
definitiveSON-related intellectual disability, congenital malformations, and failure to thriveLOFAD

This gene — mechanism propensity

DN
0.18100th %ile
GOF
0.13100th %ile
LOF
0.84top 5%

The highest-scoring mechanism for this gene is loss-of-function (haploinsufficiency).

LOFprediction above median · 1 literature citation · 95% of P/LP variants are LoF · LOEUF 0.12 · ClinGen HI: Sufficient evidence for dosage pathogenicity

Literature Evidence

LOFDetailed phenotyping of 14 patients with SON haploinsufficiency identified kidney anomalies in 8 patients, including horseshoe kidney, unilateral renal hypoplasia, and renal cysts.1

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

References

  1. 1.PMID 31005274

ClinVar Variant Classifications

1776 submitted variants in ClinVar

Classification Summary

Pathogenic107
Likely Pathogenic47
VUS764
Likely Benign680
Benign103
Conflicting57
107
Pathogenic
47
Likely Pathogenic
764
VUS
680
Likely Benign
103
Benign
57
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
105
1
1
0
107
Likely Pathogenic
42
3
2
0
47
VUS
3
740
14
7
764
Likely Benign
1
235
25
419
680
Benign
2
61
18
22
103
Conflicting
57
Total1531,040604481,758

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

65 pathogenic / likely-pathogenic (of 76) ClinVar copy-number / structural variants overlap SON — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

SON · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Carcinoma, Non-Small-Cell LungNeoplasm Metastasis

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

RECRUITING
NCT06119581Phase PHASE3Eli Lilly and CompanyStarted 2023-12-21
LY3537982PembrolizumabPlacebo
Metastatic Solid TumorAdvanced Cancer

High Definition Medicine for Solid Tumors Oncology

RECRUITING
NCT06590506Centro Nacional de Investigaciones Oncologicas CARLOS IIIStarted 2023-03-02
Wearable
Chronic Migraine HeadacheRadiofrequency AblationGreater Occipital Nerve Block

The Effect of Interventional Procedures on Serum CGRP and PACAP-38 Levels in Chronic Migraine

ACTIVE NOT RECRUITING
NCT07395908Phase NAAydin Adnan Menderes UniversityStarted 2025-05-29
Greater occipital nerve Pulse radiofrequencyGreater occipital nerve block
16P11.2 Deletion Syndrome16p11.2 Duplications1Q21.1 Deletion

Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight

RECRUITING
NCT01238250Simons SearchlightStarted 2010-10
Multiple Myeloma in Relapse

Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

ACTIVE NOT RECRUITING
NCT06282978Phase PHASE2PETHEMA FoundationStarted 2023-11-23
Elranatamab (PF-06863135)
Breast CancerHER2-negative Breast CancerHormone Receptor Positive Tumor

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

RECRUITING
NCT05982093Phase PHASE2SOLTI Breast Cancer Research GroupStarted 2023-02-03
ElacestrantTriptorelinTamoxifen 20 mg
Lung Cancer - Non Small CellEGFR Exon 19 Deletion Mutation

Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients

RECRUITING
NCT06659458Our Lady of the Lake HospitalStarted 2025-01-01
blood drawGene sequencing
Non Small Cell Lung Cancer

Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients

ACTIVE NOT RECRUITING
NCT04127110Phase PHASE2European Organisation for Research and Treatment of Cancer - EORTCStarted 2020-11-17
Lorlatinib
Breast Cancer and Pregnancy

Registry Study of Pregnancy and Breast Cancer

ACTIVE NOT RECRUITING
NCT04603820Spanish Breast Cancer Research GroupStarted 2019-11-18
Carcinoma, Non-Small-Cell Lung

A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

RECRUITING
NCT07230691Janssen Research & Development, LLCStarted 2025-12-03
Non-small Cell Lung Cancer

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

ACTIVE NOT RECRUITING
NCT03940703Phase PHASE2EMD Serono Research & Development Institute, Inc.Started 2019-09-19
TepotinibOsimertinib
Symptomatic Genetic Dilated Cardiomyopathy

A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

RECRUITING
NCT07210723Phase PHASE2, PHASE3Kardigan, Inc.Started 2026-02-13
danicamtivPlacebo